



# FACT SHEET

Agency for Healthcare Research and Quality • 2101 East Jefferson Street • Rockville, MD 20852

Rec'd [unclear] 7/6

## Centers for Education and Research on Therapeutics

### Background

The Centers for Education and Research on Therapeutics (CERTs) program is a national initiative to increase awareness of the benefits and risks of new, existing, or combined uses of therapeutics through education and research. The CERTs concept grew out of a recognition that physicians need more information about the therapies they prescribe. Although information is available through the pharmaceutical industry, continuing medical education programs, professional organizations, and peer-reviewed literature, comparative information about the risks and benefits of new and older agents and about drug interactions is limited.

Since 1992, the Agency for Healthcare Research and Quality (AHRQ, formerly the Agency for Health Care Policy and Research) has funded studies focused on patient outcomes associated with pharmaceutical therapy. Through this Pharmaceutical Outcomes Program, these grants addressed many important questions regarding the management of drug prescribing.

At the same time that medical products improve the lives of many patients, significant numbers of adverse events and inappropriate product use cause serious impairment to the health of others. Guidance on appropriate product use, prevention of errors and adverse effects, and cost-effective use of new and existing products is limited, indicating that health professionals need more complete information about the drugs and biologics they prescribe and the devices they use and that practices associated with their use should be improved.

To address these issues, Congress authorized the CERTs demonstration program as part of the Food and Drug Administration Modernization Act of 1997. Because of its demonstrated expertise in pharmaceutical outcomes

research, AHRQ was given responsibility for administration of the program. AHRQ awarded the first CERTs cooperative agreements in September 1999; the full CERTs program was made permanent in December of that year as part of the Healthcare Research and Quality Act of 1999 (Public Law 106-129).

### Purpose

The research conducted by the CERTs program has three major aims:

1. *To increase awareness* of both the uses and risks of new drugs and drug combinations, biological products, and devices as well as of mechanisms to improve their safe and effective use.
2. *To provide clinical information* to patients and consumers; health care providers; pharmacists, pharmacy benefit managers, and purchasers; health maintenance organizations and health care delivery systems; insurers; and government agencies.
3. *To improve quality while reducing cost of care* by increasing the appropriate use of pharmaceuticals and biological products and devices and by preventing their adverse effects and consequences of these effects (such as unnecessary hospitalizations).

### CERTs Implementation

AHRQ implemented the CERTs program in September 1999 when it awarded initial 3-year cooperative agreements to support the first four Centers. Each Center will focus on therapies used in a particular patient population or therapeutic area (see box).

---

*AHRQ is the lead agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services. AHRQ, formerly known as the Agency for Health Care Policy and Research (AHCPR), sponsors and conducts research that provides evidence-based information on health care outcomes; quality; and cost, use, and access. The information helps health care decisionmakers—patients and clinicians, health system leaders, purchasers, and policymakers—make more informed decisions and improve the quality of health care services.*



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service

00N-0001

TS 14

Center	Emphasis
<b>Duke University (U18 HS10548)</b> Principal investigator: <u>Robert Califf, M.D.</u>	Approved drugs and therapeutic devices in cardiovascular medicine
<b>Georgetown University (U18 HS10385)</b> Principal investigator: Raymond Woosley, M.D.	Reduction of drug interactions, particularly in women
<b>University of North Carolina (U18 HS10397)</b> Principal investigator: William Campbell, Ph.D.	Rational use of therapeutics in the pediatric population
<b>Vanderbilt University (U18 HS10384)</b> Principal investigator: Wayne Ray, Ph.D.	Prescription medication use in the Medicaid managed care population

### Structure and Administration

Duke University coordinates CERTs activities among the four Centers. There is a permanent steering committee composed of the CERTs principal investigators; representatives from AHRQ, FDA, and the National Institutes of Health; and three at-large members. Work groups of representatives from all of the Centers address broader issues related to the CERTs effort, such as quality of care and use of databases in research. AHRQ, in consultation with FDA, administers the CERTs program. AHRQ's Center for Outcomes and Effectiveness Research oversees the CERTs program and provides technical assistance and research support to the Centers.

### For More Information

For more information on the CERTs program, visit the AHRQ Web site ([www.ahrq.gov](http://www.ahrq.gov)) or contact:

Lynn Bosco, M.D., M.P.H.  
 CERTs Program Officer  
 Agency for Healthcare Research and Quality  
 Center for Outcomes and Effectiveness Research  
 6010 Executive Blvd., Suite 300  
 Rockville, MD 20852  
 Phone: 301-594-2416  
 Fax: 301-594-3211  
 Email: [lbosco@ahrq.gov](mailto:lbosco@ahrq.gov)

